annual EBIT:
$4.12B+$450.35M(+12.28%)Summary
- As of today (September 17, 2025), TAK annual earnings before interest & taxes is $4.12 billion, with the most recent change of +$450.35 million (+12.28%) on March 1, 2025.
- During the last 3 years, TAK annual EBIT has fallen by -$1.32 billion (-24.23%).
- TAK annual EBIT is now -24.23% below its all-time high of $5.43 billion, reached on March 31, 2022.
Performance
TAK EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBIT:
$1.32B+$1.12B(+559.67%)Summary
- As of today (September 17, 2025), TAK quarterly earnings before interest & taxes is $1.32 billion, with the most recent change of +$1.12 billion (+559.67%) on June 1, 2025.
- Over the past year, TAK quarterly EBIT has dropped by -$90.88 million (-6.45%).
- TAK quarterly EBIT is now -45.17% below its all-time high of $2.41 billion, reached on June 30, 2021.
Performance
TAK quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBIT:
$3.82B-$90.88M(-2.32%)Summary
- As of today (September 17, 2025), TAK TTM earnings before interest & taxes is $3.82 billion, with the most recent change of -$90.88 million (-2.32%) on June 1, 2025.
- Over the past year, TAK TTM EBIT has increased by +$939.90 million (+32.60%).
- TAK TTM EBIT is now -29.21% below its all-time high of $5.40 billion, reached on September 30, 2021.
Performance
TAK TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
TAK EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.3% | -6.5% | +32.6% |
| 3 y3 years | -24.2% | -1.1% | -6.8% |
| 5 y5 years | +47.9% | -5.7% | -0.6% |
TAK EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -24.2% | +12.3% | -8.0% | +752.5% | -16.7% | +32.6% |
| 5 y | 5-year | -24.2% | +47.9% | -45.2% | +752.5% | -29.2% | +32.6% |
| alltime | all time | -24.2% | +896.7% | -45.2% | +151.0% | -29.2% | +347.3% |
TAK EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $1.32B(+559.7%) | $3.82B(-2.3%) |
| Mar 2025 | $4.12B(+12.3%) | $199.96M(-79.9%) | $3.91B(-3.9%) |
| Dec 2024 | - | $994.58M(-24.1%) | $4.07B(+0.9%) |
| Sep 2024 | - | $1.31B(-7.1%) | $4.04B(+40.1%) |
| Jun 2024 | - | $1.41B(+291.7%) | $2.88B(-0.8%) |
| Mar 2024 | $3.67B(-24.5%) | $359.98M(-62.5%) | $2.91B(-11.4%) |
| Dec 2023 | - | $958.85M(+519.7%) | $3.28B(-10.0%) |
| Sep 2023 | - | $154.72M(-89.2%) | $3.65B(-20.5%) |
| Jun 2023 | - | $1.43B(+94.9%) | $4.59B(+2.2%) |
| Mar 2023 | $4.86B(-10.6%) | $735.82M(-44.4%) | $4.49B(+7.6%) |
| Dec 2022 | - | $1.32B(+20.7%) | $4.17B(+1.7%) |
| Sep 2022 | - | $1.10B(-17.8%) | $4.10B(-0.1%) |
| Jun 2022 | - | $1.33B(+219.5%) | $4.10B(-20.7%) |
| Mar 2022 | $5.43B(+28.7%) | $417.57M(-66.6%) | $5.18B(-1.9%) |
| Dec 2021 | - | $1.25B(+13.7%) | $5.28B(-2.3%) |
| Sep 2021 | - | $1.10B(-54.3%) | $5.40B(+2.8%) |
| Jun 2021 | - | $2.41B(+365.3%) | $5.25B(+23.7%) |
| Mar 2021 | $4.22B(+51.6%) | $517.03M(-62.5%) | $4.24B(-2.6%) |
| Dec 2020 | - | $1.38B(+44.7%) | $4.36B(+12.9%) |
| Sep 2020 | - | $951.87M(-31.9%) | $3.86B(+0.4%) |
| Jun 2020 | - | $1.40B(+121.4%) | $3.85B(+21.3%) |
| Mar 2020 | $2.78B(+41.1%) | $631.33M(-28.2%) | $3.17B(+69.1%) |
| Dec 2019 | - | $879.06M(-6.2%) | $1.87B(+0.3%) |
| Sep 2019 | - | $937.35M(+29.6%) | $1.87B(+24.3%) |
| Jun 2019 | - | $723.17M(-208.8%) | $1.50B(-7.8%) |
| Mar 2019 | $1.97B(+11.9%) | -$664.71M(-176.2%) | $1.63B(-30.3%) |
| Dec 2018 | - | $872.83M(+52.7%) | $2.34B(+12.1%) |
| Sep 2018 | - | $571.47M(-32.8%) | $2.09B(+3.3%) |
| Jun 2018 | - | $850.39M(+1829.9%) | $2.02B(+10.4%) |
| Mar 2018 | $1.76B(+119.4%) | $44.06M(-92.9%) | $1.83B(+11.8%) |
| Dec 2017 | - | $620.48M(+22.7%) | $1.64B(-1.3%) |
| Sep 2017 | - | $505.62M(-23.4%) | $1.66B(+36.1%) |
| Jun 2017 | - | $659.79M(-543.5%) | $1.22B(+20.7%) |
| Mar 2017 | $803.16M(-43.9%) | -$148.76M(-123.2%) | $1.01B(+0.9%) |
| Dec 2016 | - | $642.23M(+872.3%) | $1.00B(+17.9%) |
| Sep 2016 | - | $66.05M(-85.3%) | $848.49M(-33.2%) |
| Jun 2016 | - | $450.26M(-385.0%) | $1.27B(+3.7%) |
| Mar 2016 | $1.43B(-19.6%) | -$157.99M(-132.2%) | $1.23B(-201.8%) |
| Dec 2015 | - | $490.16M(+0.3%) | -$1.20B(-14.7%) |
| Sep 2015 | - | $488.61M(+20.8%) | -$1.41B(-7.8%) |
| Jun 2015 | - | $404.46M(-115.6%) | -$1.53B(-1.1%) |
| Mar 2015 | $1.78B(+22.6%) | -$2.59B(-1012.1%) | -$1.55B(-270.2%) |
| Dec 2014 | - | $283.55M(-23.3%) | $908.02M(-31.0%) |
| Sep 2014 | - | $369.47M(-4.7%) | $1.32B(-10.8%) |
| Jun 2014 | - | $387.51M(-392.4%) | $1.47B(-6.1%) |
| Mar 2014 | $1.45B(+61.5%) | -$132.50M(-119.2%) | $1.57B(+12.4%) |
| Dec 2013 | - | $691.15M(+30.8%) | $1.40B(+14.1%) |
| Sep 2013 | - | $528.53M(+9.4%) | $1.22B(-4.4%) |
| Jun 2013 | - | $483.13M(-258.1%) | $1.28B(-18.9%) |
| Mar 2013 | $900.28M | -$305.50M(-158.9%) | $1.58B(-16.2%) |
| Dec 2012 | - | $518.73M(-11.4%) | $1.89B(-8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $585.25M(-25.1%) | $2.07B(-23.5%) |
| Jun 2012 | - | $781.63M(>+9900.0%) | $2.70B(-19.2%) |
| Mar 2012 | $3.36B(-21.7%) | $100.80K(-100.0%) | $3.34B(-11.2%) |
| Dec 2011 | - | $698.05M(-42.8%) | $3.76B(-14.9%) |
| Sep 2011 | - | $1.22B(-14.3%) | $4.42B(-2.8%) |
| Jun 2011 | - | $1.43B(+239.2%) | $4.55B(+5.8%) |
| Mar 2011 | $4.29B(-5.3%) | $420.17M(-69.0%) | $4.30B(-6.2%) |
| Dec 2010 | - | $1.36B(+0.4%) | $4.59B(+2.0%) |
| Sep 2010 | - | $1.35B(+14.8%) | $4.50B(+2.3%) |
| Jun 2010 | - | $1.18B(+66.8%) | $4.40B(-2.5%) |
| Mar 2010 | $4.52B(+48.5%) | $705.60M(-44.3%) | $4.51B(-0.1%) |
| Dec 2009 | - | $1.27B(+1.3%) | $4.52B(-7.1%) |
| Sep 2009 | - | $1.25B(-3.2%) | $4.86B(+4.4%) |
| Jun 2009 | - | $1.29B(+81.6%) | $4.66B(+49.8%) |
| Mar 2009 | $3.05B(-17.7%) | $710.43M(-55.9%) | $3.11B(+21.3%) |
| Dec 2008 | - | $1.61B(+54.5%) | $2.56B(+16.7%) |
| Sep 2008 | - | $1.04B(-504.5%) | $2.19B(+4.5%) |
| Jun 2008 | - | -$257.90M(-257.2%) | $2.10B(-41.9%) |
| Mar 2008 | $3.70B(-5.6%) | - | - |
| Mar 2008 | - | $164.05M(-86.8%) | $3.62B(-11.5%) |
| Dec 2007 | - | $1.25B(+31.3%) | $4.09B(+0.0%) |
| Sep 2007 | - | $948.90M(-24.6%) | $4.09B(+1.3%) |
| Jun 2007 | - | $1.26B(+98.5%) | $4.03B(+2.4%) |
| Mar 2007 | $3.92B(+10.2%) | - | - |
| Mar 2007 | - | $634.00M(-49.1%) | $3.94B(+4.0%) |
| Dec 2006 | - | $1.24B(+38.9%) | $3.79B(+3.6%) |
| Sep 2006 | - | $896.00M(-23.0%) | $3.65B(+4.3%) |
| Jun 2006 | - | $1.16B(+141.9%) | $3.50B(-1.7%) |
| Mar 2006 | $3.56B(-0.7%) | - | - |
| Mar 2006 | - | $481.05M(-56.8%) | $3.56B(+1.2%) |
| Dec 2005 | - | $1.11B(+49.6%) | $3.52B(-1.3%) |
| Sep 2005 | - | $743.72M(-39.2%) | $3.56B(-3.6%) |
| Jun 2005 | - | $1.22B(+179.6%) | $3.70B(+3.0%) |
| Mar 2005 | $3.58B(+9.0%) | - | - |
| Mar 2005 | - | $437.32M(-62.3%) | $3.59B(+13.9%) |
| Dec 2004 | - | $1.16B(+32.5%) | $3.15B(+58.3%) |
| Sep 2004 | - | $875.51M(-21.5%) | $1.99B(+78.5%) |
| Jun 2004 | - | $1.12B | $1.12B |
| Mar 2004 | $3.29B(+29.0%) | - | - |
| Mar 2003 | $2.55B(+13.2%) | - | - |
| Mar 2002 | $2.25B(+10.1%) | - | - |
| Mar 2001 | $2.04B(+32.8%) | - | - |
| Mar 2000 | $1.54B(+37.5%) | - | - |
| Mar 1999 | $1.12B(+20.8%) | - | - |
| Mar 1998 | $926.79M(-17.9%) | - | - |
| Mar 1997 | $1.13B(-3.5%) | - | - |
| Mar 1996 | $1.17B(+20.7%) | - | - |
| Mar 1995 | $969.05M(+36.5%) | - | - |
| Mar 1994 | $709.75M(+30.9%) | - | - |
| Mar 1993 | $542.38M(+5.8%) | - | - |
| Mar 1992 | $512.44M(+24.1%) | - | - |
| Mar 1991 | $413.00M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
- What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
What is Takeda Pharmaceutical Company Limited annual earnings before interest & taxes?
The current annual EBIT of TAK is $4.12B
What is the all time high annual EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual earnings before interest & taxes is $5.43B
What is Takeda Pharmaceutical Company Limited annual EBIT year-on-year change?
Over the past year, TAK annual earnings before interest & taxes has changed by +$450.35M (+12.28%)
What is Takeda Pharmaceutical Company Limited quarterly earnings before interest & taxes?
The current quarterly EBIT of TAK is $1.32B
What is the all time high quarterly EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly earnings before interest & taxes is $2.41B
What is Takeda Pharmaceutical Company Limited quarterly EBIT year-on-year change?
Over the past year, TAK quarterly earnings before interest & taxes has changed by -$90.88M (-6.45%)
What is Takeda Pharmaceutical Company Limited TTM earnings before interest & taxes?
The current TTM EBIT of TAK is $3.82B
What is the all time high TTM EBIT for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM earnings before interest & taxes is $5.40B
What is Takeda Pharmaceutical Company Limited TTM EBIT year-on-year change?
Over the past year, TAK TTM earnings before interest & taxes has changed by +$939.90M (+32.60%)